ArticleOncotarget2017

Ladarixin, a dual CXCR1/2 inhibitor, attenuates experimental melanomas harboring different molecular defects by affecting malignant cells and tumor microenvironment.

Daria Marley Kemp et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.